$135,607,236
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF THE FRONTLINEODP(TM) SYSTEM FOR PRODUCING A POINT OF CARE PLASMA PRODUCT FOR TRANSFUSION. THE SCOPE IS DEFINED IN THE SOW BELOW.
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Latest obligation on a 2021 contract to develop FrontlineODP, a point-of-care plasma transfusion system for emergency medical use.
Portable plasma production could transform emergency trauma care and disaster response by enabling rapid blood product availability outside traditional hospital infrastructure.
Success requires integration of microfluidics, plasma separation, and portable medical device manufacturing—likely involving specialized component suppliers and clinical validation partners.
Point-of-care blood products are strategically important for military readiness and disaster resilience; advancing U.S. domestic capability reduces dependence on centralized supply chains vulnerable to disruption.
Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-25. Cost: $0.003120.
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier CONT_AWD_75A50121C00059_7505_-NONE-_-NONE-.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.